Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMERAN: APBI vs Endocrine Therapy in Low Risk Breast Cancer Patients Over 65
NCT05472792Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2022
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: EORTC Quality of Life Questionnaire C30 at 1 year and EORTC Quality of Life Questionnaire BR45 at 1 year. Started May 2022; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05472792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472792.